Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 22837204)

1.

A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection.

Goo L, Jalalian-Lechak Z, Richardson BA, Overbaugh J.

J Virol. 2012 Oct;86(19):10857-61. doi: 10.1128/JVI.01414-12. Epub 2012 Jul 25.

2.

HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.

Mabuka J, Goo L, Omenda MM, Nduati R, Overbaugh J.

AIDS. 2013 Jun 19;27(10):1535-44. doi: 10.1097/QAD.0b013e32835faba5.

3.

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.

Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR.

J Virol. 2015 Mar;89(5):2659-71. doi: 10.1128/JVI.03136-14. Epub 2014 Dec 17.

PMID:
25520506
4.

Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.

Andrabi R, Kumar R, Bala M, Nair A, Biswas A, Wig N, Kumar P, Pal R, Sinha S, Luthra K.

Virol J. 2012 Sep 12;9:196. doi: 10.1186/1743-422X-9-196.

5.

Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.

Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S, Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR.

Sci Transl Med. 2014 May 14;6(236):236ra63. doi: 10.1126/scitranslmed.3008104.

7.

Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.

Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, Langedijk JP, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Virol. 2012 Nov;86(22):12115-28. doi: 10.1128/JVI.01632-12. Epub 2012 Aug 29.

8.

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A.

PLoS One. 2010 Jan 20;5(1):e8805. doi: 10.1371/journal.pone.0008805.

9.

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S.

PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254.

11.

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.

12.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

13.

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S.

J Virol. 2002 Sep;76(18):9035-45.

14.

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H.

J Virol. 2007 Aug;81(16):8533-42. Epub 2007 May 23.

16.

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, Zolla-Pazner S.

Int Immunol. 1997 Sep;9(9):1281-90.

17.

HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.

Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, McKee K, Seaman MS, Bailer RT, Mascola JR.

J Virol. 2012 Mar;86(6):3393-7. doi: 10.1128/JVI.06745-11. Epub 2012 Jan 18.

19.

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR.

J Virol. 2007 Jun;81(12):6548-62. Epub 2007 Apr 4.

20.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk